The black box warning on antidepressants states that these medications increase the risk of suicidal thinking and behavior in children, adolescents, and young adults up to age 24. It is the strongest warning the FDA can place on a prescription drug, printed inside a bold black border on the medication’s label. The warning applies to antidepressants of every class, not just one type.
What the Warning Says
The FDA requires all antidepressant labels to state that these drugs increase the risk of suicidal thoughts and actions in young people being treated for depression and other psychiatric conditions. The label instructs that anyone prescribing an antidepressant to a child or adolescent must weigh this risk against the clinical need for the medication. It also directs that patients starting treatment should be closely watched for worsening symptoms, suicidal thoughts, or unusual behavioral changes, and that families and caregivers should be told to monitor the patient and stay in contact with the prescriber.
Which Medications Carry the Warning
The warning covers all antidepressant drugs regardless of class. That includes SSRIs like fluoxetine (Prozac) and sertraline (Zoloft), SNRIs like venlafaxine (Effexor), tricyclics, MAOIs, and atypical antidepressants like bupropion (Wellbutrin). If a medication is classified as an antidepressant, it carries this label.
Who the Warning Applies To
The original 2004 warning (which took effect in January 2005) focused on children and adolescents younger than 18. In May 2007, the FDA expanded it to include young adults through age 24. That broader warning remains in effect today. Notably, the clinical trial data that prompted the warning showed a different pattern in older adults: for patients 25 and older, antidepressants did not appear to increase suicidal thinking compared to placebo, and in adults 65 and older, they appeared to reduce it.
The Numbers Behind the Warning
The risk that prompted this warning is real but statistically small in absolute terms. A re-analysis of the FDA’s clinical trial database found that suicides occurred in about 0.116% of patients on antidepressants compared to 0.040% on placebo. Suicide attempts occurred in roughly 0.71% of antidepressant groups versus 0.30% of placebo groups. Put another way, the data suggest approximately 77 additional suicides and 413 additional suicide attempts per 100,000 antidepressant users beyond what would occur on placebo. No completed suicides occurred in pediatric trials specifically, but suicidal thinking roughly doubled among young patients on antidepressants compared to those on placebo.
These are averages across large trial populations. For any individual, the risk depends on their specific condition, age, medication, and other factors.
Why Antidepressants Might Increase Risk
Researchers have proposed several explanations for why antidepressants could, paradoxically, worsen suicidal thoughts in some patients, particularly early in treatment.
The most widely discussed theory involves a timing mismatch. Antidepressants can restore physical energy and motivation before they lift a person’s depressed mood. This creates a window where someone still feels hopeless but now has the energy to act on those feelings, a combination that didn’t exist when they were too lethargic to act.
A related concern is akathisia, an intense inner restlessness that some patients experience as a side effect. This sensation can feel unbearable and, in severe cases, can drive agitation and impulsive behavior. Some patients also experience a worsening of anxiety, insomnia, or irritability in the early weeks of treatment.
In patients with unrecognized bipolar disorder, antidepressants can trigger manic or hypomanic episodes. When mania mixes with lingering depressive symptoms, it creates a volatile combination of despair, impulsivity, and high energy that carries elevated suicide risk.
For a small percentage of patients, depression itself may paradoxically worsen on an antidepressant, particularly if their specific subtype of depression responds poorly to the medication. This can increase agitation and, in rare cases, psychotic symptoms.
What to Watch For
The FDA advises patients and families to watch for new or worsening symptoms during the first weeks and months of treatment, or whenever the dose changes. Specific red flags include increased anxiety, panic attacks, agitation, irritability, insomnia, impulsivity, hostility, and signs of mania such as racing thoughts, unusual energy, or reckless behavior. Any emergence of suicidal thoughts or self-harm behavior warrants immediate contact with a prescriber.
The highest-risk period is generally the first few weeks after starting a medication or adjusting a dose. This is when the energy-before-mood-improvement mismatch is most likely to occur, and when side effects like akathisia tend to appear.
The Controversy Over Unintended Consequences
The black box warning has been one of the most debated regulatory decisions in modern psychiatry. A growing body of research suggests the warning may have done more harm than good at a population level. A 2024 systematic review published in Health Affairs, covering studies from 2003 to 2022, found that after the warnings were added, doctor visits for depression dropped 20% to 40%, antidepressant prescribing fell 20% to 50% among young people, and poisonings and suicides abruptly increased.
The concern is straightforward: the warning scared patients, families, and doctors away from medications that, for most people, reduce suicide risk. Depression itself is a far greater driver of suicide than antidepressant side effects, and when fewer people get treated, more people remain in crisis. Stephen Soumerai, a professor of population medicine at Harvard Medical School who led the Health Affairs review, called on the FDA to downgrade the boxed warning to a standard label warning, arguing the evidence of harm from the warning itself now outweighs its benefits.
Some clinicians have been more blunt. Jeffrey Strawn, a psychiatry researcher at the University of Cincinnati, has said the warnings “have decreased physicians’ and other clinicians’ comfort and tendency to prescribe” and have been actively harmful. Other experts, including Dara Sakolsky at the University of Pittsburgh, have similarly urged the FDA to “lower the temperature” around the warnings.
When asked about the Health Affairs findings, an FDA spokesperson said the agency “does not comment on specific studies but evaluates them as part of the body of evidence.” As of early 2025, the warning remains unchanged.
Balancing Risk and Benefit
The black box warning doesn’t mean antidepressants are unsafe for young people. It means the first weeks of treatment require close attention. For the vast majority of patients, antidepressants reduce suicidal thinking over time. The risk flagged by the warning is small in absolute terms, concentrated in the early treatment period, and manageable with proper monitoring. Untreated depression, by contrast, carries a much larger and sustained risk of suicide.
If you or someone in your family is starting an antidepressant, the practical takeaway is simple: stay in close contact with the prescriber during the first month, report any new or worsening symptoms promptly, and understand that early side effects like restlessness or increased anxiety are not uncommon and can be addressed with dose adjustments or medication changes.